11:30–11:40 Welcome and introduction
Everett Vokes (USA)
11:40–12:05 What is the current clinical status of novel immunotherapies in advanced NSCLC?
Luis Paz-Ares (Spain)
12:05–12:30 What does the latest evidence reveal for emerging MET inhibitors?
Ross Camidge (USA)
12:30–12:55 Are we optimally prepared to provide personalized treatment strategies?
Martin Reck (Germany)
12:55–13:00 Summary and adjournment
Everett Vokes (USA)

Ology Medical Education

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.